Key result
Marshall-Plan trial tests if vein of Marshall ethanol plus linear ablation beats PVI alone in persistent AF.
Why the study?
Ablation strategies beyond PVI remain controversial, and whether adding systematic vein of Marshall ethanol infusion and empirical linear ablation improves outcomes in persistent AF remains to be demonstrated.
Does the Marshall-Plan approach (PVI + VOM ethanol infusion + linear ablation) improve 2-year freedom from atrial arrhythmias compared to PVI alone in patients with persistent AF?
RCT (n=262)
parallel-group
Yes
Does the Marshall-Plan approach (PVI + VOM ethanol infusion + linear ablation) improve 2-year freedom from atrial arrhythmias compared to PVI alone in patients with persistent AF?
This trial design outlines a randomized comparison of the Marshall-Plan ablation strategy versus PVI alone for persistent atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Marshall-Plan trial will test if VOM ethanol infusion plus linear ablation augments PVI in persistent AF; leaves open superiority until results.
BACKGROUND: Beyond pulmonary veins isolation (PVI), the ablation strategy that has prevailed over the past two decades remains controversial: (1) the left atrium partition using linear lesions ("cox-maze" strategy); (2) the mapping of the left atrium in atrial fibrillation (AF) to identify and localize the arrhythmia sources. Both methods have failed to demonstrate superiority compared to PVI alone. Whether the addition of a systematic vein of Marshall (VOM) ethanol infusion and empirical linear ablation to PVI (Marshall-Plan) improves outcomes in patients with persistent AF remains to be demonstrated. OBJECTIVES: To compare the 2-year freedom from any atrial arrhythmia (atrial fibrillation [AF]/atrial tachycardia [AT]) between the Marshall-Plan approach and the PVI approach in patients with persistent AF. METHODS: The Marshall Plan is a multicenter, prospective, randomized, parallel- group, controlled clinical trial of superiority conducted in nine tertiary care centers across Europe (8 centers in France, 1 center in Belgium). A total of 262 patients will be randomized in two arms: Marshall-Plan, consisting of PVI with additional ablation, including vein of Marshall ethanol infusion, and lines of block at the mitral, dome, and cavotricuspid isthmuses versus PVI alone. The main outcome will be the 2-year freedom from any arrhythmia AF/AT <30 seconds) after a single ablation procedure with or without antiarrhythmic medication. CONCLUSIONS: This randomized trial aims to determine the success and safety of adjunctive VOM ethanol infusion and linear ablation to PVI in patients with persistent AF. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04681872.
No takes yet. Share an insight, caveat, or question.
Derval et al. (2026) conducted an RCT in persistent atrial fibrillation (n=262). Marshall-Plan (PVI with vein of Marshall ethanol infusion and lines of block) vs. PVI alone was evaluated on 2-year freedom from any arrhythmia (AF/AT <30 seconds) after a single ablation procedure with or without antiarrhythmic medication. The Marshall-Plan trial will randomize 262 patients with persistent AF to evaluate if adjunctive vein of Marshall ethanol infusion and linear ablation improves 2-year outcomes versus PVI alone.
Synapse has enriched 10 related papers. Consider them for comparative context: